RxDoctor Payments Data

Cameron Nixon, MD

Internal Medicine · Tifton, GANPI 1619972304

Payments from drug & device makers

$2,377in general payments, 2019–2025

Across 153 payments — averaging $15.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$335
  • Johnson & Johnson$297
  • GSK$253
  • Astellas Pharma US Inc$206
  • Pfizer$146
  • AstraZeneca$141
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,32098%
  • Education$572%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,377 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$13,621
Medicare patients
103
Services billed
218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide227$281,608
OzempicSemaglutide201$226,343
FarxigaDapagliflozin Propanediol113$146,325
EliquisApixaban131$109,619
LinzessLinaclotide83$84,162
JanuviaSitagliptin Phosphate45$65,275
XareltoRivaroxaban48$47,883
JardianceEmpagliflozin29$30,184
RexultiBrexpiprazole14$28,703
InvokanaCanagliflozin19$27,805
TrulicityDulaglutide22$26,486
Tresiba Flextouch U-200Insulin Degludec29$20,869
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$18,415
TradjentaLinagliptin16$16,116
MovantikNaloxegol Oxalate22$15,995

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$74$308,094249 claims
Novo NordiskOzempic$335$226,343201 claims
AstraZenecaFarxiga$141$146,325113 claims
PfizerEliquis$146$109,619131 claims
MerckJanuvia, Janumet Xr, Janumet$34$93,03480 claims
AbbVieLinzess$109$84,16283 claims
Johnson & JohnsonXarelto, Invokana$297$75,68867 claims
Boehringer IngelheimJardiance, Tradjenta$15$46,30045 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$253$31,57846 claims
Otsuka America Pharmaceutical, Inc.Rexulti$37$28,70314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Tifton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →